Format

Send to

Choose Destination
Neurol Sci. 2006 May;27 Suppl 2:S159-63.

Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study.

Author information

1
Headaches and Cerebrovascular Disorders Unit, C. Besta National Neurological Institute, Via Celoria 11, I-20133, Milan, Italy. bussone@istituto-besta.it

Abstract

Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

PMID:
16688622
DOI:
10.1007/s10072-006-0593-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center